FIELD: chemistry.
SUBSTANCE: disclosed is a compound having chemical formula or a salt thereof, where: Ar is an optionally substituted heteroaryl; R1 in each case is independently selected from a group which includes halogen, lower alkyl, optionally substituted with one or more substitutes selected from fluorine, lower alkoxy, fluorine-substituted lower alkoxy, monoalkylamino, dialkylamino, -O-R5, -N(R5)-R6 and -N(R5)-C(X)-R7; m equals 0 or 1; n equals 0, 1 or 2; R2 is hydrogen or a halogen; L2 is -S(O)2-; R3 is a lower alkyl, optionally substituted with fluorine, C3-6 cycloalkyl, optionally substituted with a lower alkyl, a 5- or 6-member nitrogen-containing heterocycloalkyl, optionally substituted with one or more substitutes selected from fluorine, lower alkyl, fluorine-substituted lower alkyl, lower alkoxy, fluorine-substituted lower alkoxy, lower alkylthio or fluorine-substituted lower alkylthio, aryl, optionally substituted with a halogen, lower alkyl, optionally substituted with a halogen or lower alkoxy, optionally substituted with a halogen, or a heteroaryl, optionally substituted with a halogen or a lower alkyl; L1 is selected from a group which includes -O-, -C(R12R13)-X-, -X-C(R12R13)-, -C(R12R13)-N(R11)-, -(R11)-C(R12R13)-, -C(X)-N(R11)-, -N(R11)-C(X)-; X is O; R11 is hydrogen; R4 is hydrogen or a lower alkyl; R5 and R6 in each case are independently selected from a group which includes hydrogen, lower alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl, where each is optionally substituted with one or more substitutes selected from fluorine, lower alkoxy, fluorine-substituted lower alkoxy, lower alkylthio, fluorine-substituted lower alkylthio, monoalkylamino, dialkylamino; R7 in each case is independently selected from a group which includes lower alkyl; where the terms "lower alkyl", "lower alkoxy", "lower alkylthio", "monoalkylamino", "dialkylamino", "cycloalkyl", "heterocycloalkyl", "aryl", "heteroaryl", are as described in the claim. The invention also discloses a pharmaceutical composition for treating Raf kinase mediated diseases which is based on a compound of formula I; use of the compound of formula I to produce a medicinal agent is also disclosed.
EFFECT: novel compound which can be useful in treating diseases and conditions associated with aberrant activity of protein kinases is obtained and described.
9 cl, 13 ex, 2 tbl
Title | Year | Author | Number |
---|---|---|---|
PYRROLO[2,3-b]PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | 2006 |
|
RU2565071C2 |
PYROLLO [2,3-B]PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | 2012 |
|
RU2629999C2 |
KINASES MODULATION AND INDICATIONS FOR ITS USE | 2012 |
|
RU2631487C2 |
PYRROLO[2,3-B]PYRIDINE DERIVATIVE AS PROTEIN KINASE INHIBITORS | 2006 |
|
RU2418800C2 |
COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USE THEREOF | 2007 |
|
RU2452738C2 |
HETEROCYCLIC COMPOUNDS AND USES THEREOF | 2014 |
|
RU2680100C9 |
COMBINED THERAPY INCLUDING SGLT INHIBITORS AND DPP4 INHIBITORS | 2009 |
|
RU2481106C2 |
DIHYDROPYRIDAZINE-3,5-DIONE DERIVATIVE | 2014 |
|
RU2662832C2 |
COMPOUNDS AND METHODS FOR KINASE MODULATION AND INDICATIONS FOR THEIR USE | 2013 |
|
RU2666146C2 |
COMPOUNDS FOR USE IN TREATMENT OF MUCOSITIS | 2012 |
|
RU2606128C2 |
Authors
Dates
2013-07-10—Published
2008-07-16—Filed